Get the Stockscreener App
0.4118
2.56%
-0.0108
After Hours:
.42
0.0082
+1.99%
Can-Fite Biopharma Ltd ADR stock is traded at $0.4118, with a volume of 174.95K.
It is down -2.56% in the last 24 hours and down -33.58% over the past month.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$0.4226
Open:
$0.41
24h Volume:
174.95K
Relative Volume:
0.91
Market Cap:
$634.75K
Revenue:
$743.00K
Net Income/Loss:
$-7.63M
P/E Ratio:
-0.1373
EPS:
-3
Net Cash Flow:
-
1W Performance:
-13.29%
1M Performance:
-33.58%
6M Performance:
-63.40%
1Y Performance:
-80.94%
1-Day Range:
$0.4065
$0.42
1-Week Range:
$0.4065
$0.4814
52-Week Range:
$0.4065
$2.50
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADR
Sector
Industry
Phone
972 3 924 1114
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.4118 | 7.22M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-17 | Initiated | Maxim Group | Buy |
| Oct-19-16 | Resumed | ROTH Capital | Buy |
| Aug-29-16 | Resumed | Rodman & Renshaw | Buy |
| Nov-30-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-31-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-30-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-29-14 | Reiterated | ROTH Capital | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
View All
Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsMarket Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Market WrapUp & Stock Timing and Entry Methods - newser.com
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockTrade Ideas & Weekly Top Gainers Trade List - newser.com
Why retail traders accumulate Can Fite Biopharma Ltd Sponsored ADR stockJuly 2025 Sector Moves & Fast Exit Strategy with Risk Control - newser.com
Will Can Fite Biopharma Ltd Sponsored ADR stock benefit from mergersMarket Sentiment Report & Real-Time Volume Spike Alerts - fcp.pa.gov.br
Why Can Fite Biopharma Ltd Sponsored ADR stock could rally stronglyJuly 2025 Technicals & Free Community Supported Trade Ideas - fcp.pa.gov.br
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong analyst pickQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong buy callTake Profit & Verified Momentum Stock Ideas - newser.com
Will Can Fite Biopharma Ltd Sponsored ADR stock beat growth indexesJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock could outperform next yearGlobal Markets & Weekly Return Optimization Alerts - newser.com
Why pension funds invest in Can Fite Biopharma Ltd Sponsored ADR stockJuly 2025 Selloffs & Reliable Trade Execution Plans - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock fits value portfolios2025 Bull vs Bear & Smart Allocation Stock Reports - newser.com
Is Can Fite Biopharma Ltd Sponsored ADR stock expanding market penetration2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Is Can Fite Biopharma Ltd Sponsored ADR stock a contrarian opportunityEarnings Miss & Real-Time Volume Triggers - newser.com
Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):